Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T11:10:57.771Z.
Calculation as of: 2026-10-06T11:10:57.771Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 58a2fa14633c50703c8ff5f7fcb702de1515a66dae0cc773e6a723eda01f3aaa
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$12.89B
EV/EBITDA Ratio
10.94x
TTM Avg
10.65x
3Y Avg
13.38x
5Y Avg
17.81x
Market Cap
$13.19B
EV/EBITDA Ratio
1483.24x
TTM Avg
453.42x
3Y Avg
156.61x
5Y Avg
99.99x
Market Cap
$12.52B
EV/EBITDA Ratio
29.51x
TTM Avg
24.38x
3Y Avg
21.38x
5Y Avg
20.67x
Market Cap
$12.49B
EV/EBITDA Ratio
61.12x
TTM Avg
62.42x
3Y Avg
203.15x
5Y Avg
254.34x
Market Cap
$12.17B
EV/EBITDA Ratio
21.92x
TTM Avg
25.48x
3Y Avg
21.33x
5Y Avg
21.33x
Market Cap
$12.00B
EV/EBITDA Ratio
10.07x
TTM Avg
10.02x
3Y Avg
8.91x
5Y Avg
8.81x
Market Cap
$14.16B
EV/EBITDA Ratio
93.79x
TTM Avg
953.43x
3Y Avg
953.43x
5Y Avg
953.43x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | $12.95B | N/A | N/A | N/A | N/A |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 10.94x | 10.65x | 13.38x | 17.81x |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 1483.24x | 453.42x | 156.61x | 99.99x |
| Baxter International Inc. (BAX)vs › | $12.52B | 29.51x | 24.38x | 21.38x | 20.67x |
| Penumbra, Inc. (PEN)vs › | $12.49B | 61.12x | 62.42x | 203.15x | 254.34x |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.17B | 21.92x | 25.48x | 21.33x | 21.33x |
| Encompass Health Corporation (EHC)vs › | $12.00B | 10.07x | 10.02x | 8.91x | 8.81x |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | 93.79x | 953.43x | 953.43x | 953.43x |
| DaVita Inc. (DVA)vs › | $11.47B | 7.66x | 8.94x | 9.05x | 9.12x |
| Bio-Techne Corporation (TECH)vs › | $11.36B | 32.61x | 41.13x | 35.86x | 37.45x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
